AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

Immunai Inc., a New York-based artificial intelligence and biotech company specializing in mapping the human immune system, ...

AstraZeneca is scheduled to report results for the third quarter on Tuesday. Here is what to know. CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

AstraZeneca said on Wednesday the company's China President Leon Wang is currently under investigation and is cooperating ...

Shares of AstraZeneca PLC AZN inched up 0.18% to £110.42 Monday, on what proved to be an all-around favorable trading session ...

China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.

The year 2021 was one of big impact for pharmaceutical leader AstraZeneca, which supplied over 2.5 billion doses of COVID-19 vaccines to more than 180 countries. But when it comes to ESG reporting ...